Published in Expert Rev Pharmacoecon Outcomes Res on April 01, 2002
The Common Drug Review: a NICE start for Canada? Health Policy (2005) 2.58
On the validity of area-based income measures to proxy household income. BMC Health Serv Res (2008) 1.70
Sources of variation in provincial drug spending. CMAJ (2004) 1.62
Income-based drug coverage in British Columbia: the impact on access to medicines. Healthc Policy (2006) 1.59
Income-based drug coverage in British Columbia: the impact on the distribution of financial burden. Healthc Policy (2006) 1.53
Physician labour supply in Canada: a cohort analysis. Health Econ (2009) 1.45
A cross-national study of prescription nonadherence due to cost: data from the Joint Canada-United States Survey of Health. Clin Ther (2006) 1.40
Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care (2003) 1.37
Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ (2005) 1.35
The policy analysis of 'values talk': lessons from Canadian health reform. Health Policy (2004) 1.23
Inequity in publicly funded physician care: what is the role of private prescription drug insurance? Health Econ (2009) 1.22
Physician response to pay-for-performance: evidence from a natural experiment. Health Econ (2013) 1.18
Selecting effective incentive structures in health care: A decision framework to support health care purchasers in finding the right incentives to drive performance. BMC Health Serv Res (2008) 1.15
Clinical outcomes of unstable pelvic fractures in skeletally immature patients. J Bone Joint Surg Am (2005) 1.14
Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Clin Ther (2009) 1.12
Explaining prescription drug use and expenditures using the adjusted clinical groups case-mix system in the population of British Columbia, Canada. Med Care (2010) 1.06
Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada. J Health Polit Policy Law (2010) 1.06
Access to cancer drugs in Canada: looking beyond coverage decisions. Healthc Policy (2011) 1.05
Health care access in three nations: Canada, insured America, and uninsured America. Int J Health Serv (2006) 0.98
Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. Soc Sci Med (2009) 0.93
Predictive genetic tests and health system costs. CMAJ (2003) 0.92
Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS One (2009) 0.92
Comparison of tiered formularies and reference pricing policies: a systematic review. Open Med (2009) 0.92
Physician resource planning in Canada: the need for a stronger behavioural foundation. Can Public Policy (2010) 0.92
Inequity in a market-based health system: Evidence from Canada's dental sector. Health Policy (2010) 0.92
Public and private health-care financing with alternate public rationing rules. Health Econ (2010) 0.90
Medicine by media: did a critical television documentary affect the prescribing of cyproterone--estradiol (Diane-35)? CMAJ (2005) 0.89
Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada. Health Econ (2008) 0.89
Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy (2010) 0.89
Centralized drug review processes: are they fair? Soc Sci Med (2006) 0.87
Geographic disparity in premature mortality in Ontario, 1992-1996. Int J Health Geogr (2003) 0.86
The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey. Eur J Health Econ (2011) 0.86
Internet pharmacy: prices on the up-and-up. CMAJ (2004) 0.86
Validation of human whole blood oximetry, using a hyperspectral fundus camera with a model eye. Invest Ophthalmol Vis Sci (2011) 0.85
Information behaviour of Canadian pharmaceutical policy makers. Health Info Libr J (2011) 0.83
Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction. J Gen Intern Med (2011) 0.83
A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law (2010) 0.83
Registration for public drug benefits across areas of differing ethnic composition in British Columbia, Canada. BMC Health Serv Res (2010) 0.82
Insurance coverage and the treatment of mental illness: effect on medication and provider use. J Ment Health Policy Econ (2008) 0.82
Fair reckoning: a qualitative investigation of responses to an economic health resource allocation survey. Health Expect (2012) 0.81
Health care at a premium. CMAJ (2004) 0.81
Percutaneous minimally invasive stereotactic primary radiotherapy for breast cancer. Lancet Oncol (2002) 0.80
The role of proximity to death in need-based approaches to health care. Health Policy (2012) 0.77
A three-stage approach to measuring health inequalities and inequities. Int J Equity Health (2014) 0.75
Publicly funded medical savings accounts: expenditure and distributional impacts in Ontario, Canada. Health Econ (2008) 0.75
Working with risk. Ment Health Today (2007) 0.75
The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada. Health Policy (2011) 0.75
Clinical implementation of photon beam flatness measurements to verify beam quality. J Appl Clin Med Phys (2015) 0.75